Novel oral anticoagulants in interventional cardiology
The guidelines for the management of patients treated with an oral anticoagulant therapy (OAT) undergoing elective or urgent percutaneous coronary interventions (PCI) are mainly based on the recommendations of experts, rather than on clinical evidence, because this specific group of patients in studies of interventional cardiological treatment were rarely or not presented. However, there are certain rules to be followed. In general, a triple therapy consisting of OAT, with either vitamin K antagonist (VKA) or novel oral anticoagulant (NOAC), aspirin and clopidogrel, is given after stent implantation and followed by a combination of OAT and single antiplatelet drug for up to 12 months and then OAT therapy alone. The duration of the triple therapy depends on the clinical setting (PCI in acute coronary syndrome vs elective PCI), the individual risk for bleeding and thromboembolism, as well as on the complexity of coronary artery disease.
Key words:
novel oral anticoagulants; percutaneous coronary intervention; stents; vitamin K antagonists; warfarin
OGLASI
